Quest Diagnostics slashes full-year earnings forecast


Oct 17 (Reuters) - Quest Diagnostics Inc slashed itsfull-year earnings forecast as the laboratory tests providerstruggles with cuts in Medicare reimbursement.

The company, which estimated third-quarter profit belowmarket expectations last week, reduced its earnings forecast forthe year to $3.85-$3.95 per share from $4.35-$4.50.

Analysts were expecting earnings of $4.23 per share,according to Thomson Reuters I/B/E/S.

Quest also said it expected full-year revenue about 3.5percent below the previous year. It had earlier estimatedrevenue to fall 1-2 percent. The company reported net revenue of$7.38 billion in 2012.

"Healthcare utilization and reimbursement continue to be aheadwind for our industry, and our results reflect that," ChiefExecutive Steve Rusckowski said in a statement.

The company said test volume, measured by the number ofrequisitions, rose 2 percent. Revenue per requisition fell 4.3percent, mainly due to the reimbursement pressure.

Net income from continuing operations rose to $402.7million, or $2.66 per share in the third quarter ended Sept. 30,from $158.6 million, or 98 cents per share, a year earlier.

Revenue from its diagnostics information services business,which includes clinical testing services, fell 2.4 percent.

View Comments (0)